43rd week of 2014 patent applcation highlights part 50 |
Patent application number | Title | Published |
20140315757 | DETECTION OF NUCLEIC ACID SEQUENCE DIFFERENCES USING COUPLED LIGASE DETECTION AND POLYMERASE CHAIN REACTIONS - The present invention relates to a method for identifying a target nucleotide sequence. This method involves forming a ligation product on a target nucleotide sequence in a ligation detection reaction mixture, amplifying the ligation product to form an amplified ligation product in a polymerase chain reaction (PCR) mixture, detecting the amplified ligation product, and identifying the target nucleotide sequence. Such coupling of the ligase detection reaction and the polymerase chain reaction permits multiplex detection of nucleic acid sequence difference. | 2014-10-23 |
20140315758 | CANCER ANTIGEN-SPECIFIC T-CELL RECEPTOR GENE, PEPTIDE ENCODED BY THE GENE, AND USE OF THEM - Disclosed are: a nucleotide sequence and an amino acid sequence for CDR3 region of T-cell receptor (TCR) gene of WT1-specific cytotoxic T-cell (CTL) for WT1 protein; a method for the detection or treatment of cancer using the nucleotide sequence or the amino acid sequence; and a chip, a primer set, a kit, an apparatus and the like for use in the detection of cancer, each of which comprises the nucleotide sequence or the amino acid sequence. | 2014-10-23 |
20140315759 | MOLECULAR NETS ON SOLID PHASES - Disclosed is a covalently-linked multilayered three-dimensional matrix comprising capture molecules, linkers and spacers (referred to as a Molecular Net) for specific and sensitive analyte capture from a sample. Also disclosed herein is a Molecular Net comprising covalently-linked multilayered three-dimensional matrix comprising more than one type of capture molecule and more than one type of linker and may comprise one or more spacer for specific and sensitive capture of more than one type of analyte from a sample. A Molecular Net may comprise a pseudorandom nature. Use of various capture molecules, linkers and spacers in a Molecular Net may confer unique binding properties to a Molecular Net. Porosity, binding affinity, size exclusion abilities, filtration abilities, concentration abilities and signal amplification abilities of a Molecular Net may be varied and depend on the nature of components used in its fabrication. Uses of a Molecular Net may include analyte capture, analyte enrichment, analyte purification, analyte detection, analyte measurement and analyte delivery. Molecular Nets may be used in liquid phase or on solid phases such as nanomaterials, modified metal surfaces, nanospheres, microspheres, microtiter plates, slides, pipettes, cassettes, cartridges, discs, probes, lateral flow devices, microfluidics devices, microfluidics devices, optical fibers and others. | 2014-10-23 |
20140315760 | PHOTONIC BLOOD TYPING - Photonic devices, systems, and methods for detecting an analyte in a biological solution (e.g., whole blood) are provided. Representative photonic devices are optical ring resonators having nanoscale features and micron-sized diameters. Due to the compact size of these devices, many resonators can be disposed on a single substrate and tested simultaneously as a sample is passed over the devices. Typical analytes include blood cells, antibodies, and pathogens, as well as compounds indicative of the presence of blood cells or pathogens (e.g., serology). In certain embodiments, blood type can be determined through photonic sensing using a combination of direct detection of blood cells and serology. By combining the detection signals of multiple devices, the type of blood can be determined. | 2014-10-23 |
20140315761 | KITS FOR DETERMINING MALE FERTILITY BY MEASURING LEVELS OF a2v-ATPASE, G-CSF, MIP 1 alpha, MCP-1, AND METHODS AND KITS FOR IMPROVING REPRODUCTIVE OUTCOMES IN ARTIFICIAL INSEMINATION PROCEDURES - The present invention provides a kit for determining male fertility including a container system containing a plurality of enzyme-linked antibodies one of each capable of binding to analytes Atp6v0a2, G-CSF, MIP 1α, and MCP-1. The kit further includes suitable packaging and a set of instructions for using the enzyme-linked antibodies with a seminal sample to determine the fertility of the sample. | 2014-10-23 |
20140315762 | METHODS FOR TAGGING DNA-ENCODED LIBRARIES - The present invention relates to oligonucleotide-encoded libraries and methods of tagging such libraries. In particular, the methods and oligonucleotides can include one or more 2′-substituted nucleotides, such as 2′-O-methyl or 2′-fluoro nucleotides, and other conditions or reagents to enhance enzyme ligation or one or more chemical functionalities to support chemical ligation. | 2014-10-23 |
20140315763 | OIL BASED CONCENTRATED SLURRIES AND METHODS FOR MAKING AND USING SAME - New hydrocarbon based slurry compositions and drilling, fracturing, completion and production fluids including the hydrocarbon based slurry composition are disclosed, where the composition includes a hydrocarbon soluble polymer adapted to decrease particle settling rates of particulate materials present in the fluids and in the case of fluids that include hydratable materials to increase hydration properties of such materials. | 2014-10-23 |
20140315764 | Reclaimed Oil - A method to reclaim and purify an oil bound to a substrate, and a reclaimed oil obtained thereby having, relative to the oil in the bound liquid in the substrate, a lower aromatic content, improved rheological properties, improved handling properties, or a combination thereof. | 2014-10-23 |
20140315765 | TREATMENT OF A SUBTERRANEAN FORMATION WITH COMPOSITION INCLUDING A MICROORGANISM OR COMPOUND GENERATED BY THE SAME - The present invention relates to methods of treating a subterranean formation with a composition including a compound made by a microorganism or a microorganism that can make the compound. Various embodiments provide methods of using compositions for treatment of subterranean formations including exopolysaccharides or microorganisms that can make exopolysaccharides under downhole conditions. In various embodiments, the present invention provides a method of treating a subterranean formation, including providing at least one exopolysaccharide by subjecting an extremophilic or extremotolerant microorganism to conditions such that the microorganism forms the exopolysaccharide, or by subjecting a microorganism genetically modified using an extremophilic or extremotolerant microorganism to conditions such that the microorganism forms the exopolysaccharide. The method can also include contacting a composition including the exopolysaccharide with a subterranean material downhole. | 2014-10-23 |
20140315766 | Methods and Compositions of Treating a Subterranean Formation with an Optimized Treatment Fluid - Methods of treating a subterranean formation including providing a treatment fluid comprising a brine base fluid and an anionic carboxylated polysaccharide, wherein the brine base fluid comprises a concentration of salt in the range of from about 30,000 ppm to saturation and a pH in the range of from about 4 to about 8, and wherein the anionic carboxylated polysaccharide is present in the range of from about 0.05% to about 2% by weight of the treatment fluid; and introducing the treatment fluid into the subterranean formation. | 2014-10-23 |
20140315767 | Seal Compatibility Additive To Improve Fluoropolymer Seal Compatibility of Lubricant Compositions - This disclosure is directed to an additive package for a lubricant composition that provides improved compatibility with fluoropolymer seals. The additive package comprises a seal compatibility additive. The disclosure is also directed to a lubricant composition comprising a base oil and a seal compatibility additive. The seal compatibility additive improves the compatibility with fluoropolymer seals of the resultant lubricant composition. | 2014-10-23 |
20140315768 | Seal Compatibility Additive To Improve Fluoropolymer Seal Compatibility of Lubricant Compositions - This disclosure is directed to an additive package for a lubricant composition that provides improved compatibility with fluoropolymer seals. The additive package comprises a seal compatibility additive. The disclosure is also directed to a lubricant composition comprising a base oil and a seal compatibility additive. The seal compatibility additive improves the compatibility with fluoropolymer seals of the resultant lubricant composition. | 2014-10-23 |
20140315769 | Lubricant Composition - A lubricant composition is substantially free of water and includes a base oil present in an amount of greater than 85 parts by weight per 100 parts by weight of the lubricant composition, includes an antioxidant, and includes one or more alkylethercarboxylic acid corrosion inhibitor(s) present in an amount of from 0.01 to 1 weight percent based on a total weight of said lubricant composition. The one or more alkylethercarboxylic acid corrosion inhibitor(s) have the formula; | 2014-10-23 |
20140315770 | LUBRICATING COMPOSITION - A lubricating composition for use in the crankcase of an engine comprising a base oil and one or more additives, wherein the lubricating composition comprises from 0.01 wt % to 5 wt %, by weight of the lubricating composition, of one or more liquid crystal compounds, wherein the one or more liquid crystal compounds is a terphenyl compound. | 2014-10-23 |
20140315771 | LUBRICANT OIL COMPOSITION FOR TRANSMISSIONS - A lubricating oil composition for a transmission includes a base oil in a range of 1 mass % to 80 mass %, the base oil having a kinematic viscosity at 40 degrees C. in a range of 0.5 mm | 2014-10-23 |
20140315772 | FRAGRANCE MATERIALS - The present application relates to perfume raw materials, perfumes, perfume delivery systems and consumer products comprising such perfume raw materials, perfumes and/or such perfume delivery systems, as well as processes for making and/or using such perfume raw materials, perfume delivery systems and consumer products. Such perfume raw materials, perfumes, perfume delivery systems and consumer products can reduce the impact of certain harsh odours. | 2014-10-23 |
20140315773 | NOVEL METHOD FOR THE FORMULATION OF NAIL POLISH REMOVER - A nail polish remover that is safer and more environmentally friendly than conventional acetone-based and petrochemical-based nail polish removers containing a mixture of water and at least one lower alkyl acetate, and an amount of an emulsifier that is sufficient to emulsify the alkyl acetate to prevent phase separation of the mixture. Exemplary compositions include, as the lower alkyl acetate, n-butyl acetate in an amount of from 10% to 60% by volume, ethanol, as the emulsifier, in an amount of from 0 to 20% by volume, and the balance being water. | 2014-10-23 |
20140315774 | SOLVENT COMPOSITIONS INCLUDING 1-CHLORO-3,3,3-TRIFLUOROPROPENE AND USES THEREOF - The present invention relates to solvent compositions including an effective amount of 1-chloro-3,3,3-trifluoropropene and uses thereof. In certain aspects, such solvent compositions may be applied to the surface of an article or portion of an article having an ink or ink-based marking so as to remove the ink or ink-based marking without deleteriously impacting the article or surface of the article. | 2014-10-23 |
20140315775 | USE AND PRODUCTION OF CITRATE-STABLE NEUTRAL METALLOPROTEASES - The present invention provides methods and compositions comprising at least one neutral metalloprotease enzyme that has improved stability in the presence of a metal chelator. In some embodiments, the neutral metalloprotease finds use in cleaning and other applications comprising citrate. In some particularly preferred embodiments, the present invention provides methods and compositions comprising variant neutral metalloprotease(s) engineered to resist citrate-induced autolysis. | 2014-10-23 |
20140315776 | Container for use in a washing process - The present invention provides a deformable water soluble or water dispersible outer pouch containing a detergent composition, the detergent composition comprising at least one phase in solid form and at least one liquid phase with at least one solid phase predominantly surrounded by a liquid phase. The pouches exhibit good physical and chemical stability and can also provide for sequential release of its ingredients. | 2014-10-23 |
20140315777 | DETERGENT PACKET - A detergent packet includes a liquid detergent contained within a water soluble pouch. The water soluble pouch is formed from a film including at least one of a polymer of hydrolyzed vinyl acetate and a copolymer of hydrolyzed vinyl acetate and a second monomer. The liquid detergent includes between 5 wt % and 60 wt % water and between 0.5 wt % and 15 wt % inorganic sulfate. | 2014-10-23 |
20140315778 | CLEANING COMPOSITION - Provided is an aqueous cleaning composition comprising at least one surfactant, xanthan gum, and a carbonate salt, wherein the composition has a turbidity of less than 16 NTU. Also provided is a method of cleaning a substrate by applying the cleaning composition to the substrate. | 2014-10-23 |
20140315779 | METHOD OF INCREASING THE PERFORMANCE OF CATIONIC FABRIC SOFTENERS - The present invention is method of boosting the performance of a cost-reduced liquid fabric softener comprising a quaternary surfactant fabric softener by adding a quaternary (meth)acrylic polymer that functions dually as a fabric softening active and a rheology modifier. In particular, poly[{2-(methacryloyloxy)ethyl}trimethylammonium chloride], poly[{2-(acryloyloxy)ethyl}trimethylammonium chloride], poly[{3-(methacryloyloxy)propyl}trimethylammonium chloride], and poly[{3-(acryloyloxy)propyl}trimethylammonium chloride] provide synergistic fabric softening with quaternary surfactants to provide superior fabric softening scores from cost-optimized compositions. | 2014-10-23 |
20140315780 | PRODUCT - A delivery system for an active substance, comprising a substrate on which the substance is loaded for subsequent release, wherein: (i) the substrate has been at least partially coated with a polymer using plasma deposition (preferably pulsed plasma deposition); (ii) the active substance is present as a guest molecule within a cyclodextrin inclusion complex; and (iii) the inclusion complex is bound to the polymer through a chemical linkage formed between a hydroxyl group on the cyclodextrin and a functional group on the polymer. The system may be used to control the release of an active substance such as a perfume. Also provided are methods for preparing (a) the delivery system and (b) a functionalised substrate for use as part of the system, in which the polymer is suitably reacted with a cyclodextrin using an S N 2 nucleophilic substitution reaction, in particular a Williamson ether synthesis reaction. | 2014-10-23 |
20140315781 | METHODS OF TREATING FATTY LIVER DISEASE WITH HELMINTH-DERIVED GLYCAN-CONTAINING COMPOUNDS - The present invention provides a compound comprising a helminth-derived glycan and/or glycoconjugate thereof (e.g., a compound comprising a Lewis | 2014-10-23 |
20140315782 | METHODS AND PRODUCTS FOR INCREASING FRATAXIN LEVELS AND USES THEREOF - Methods and products (e.g., recombinant proteins) are described for increasing frataxin expression/levels in a cell, as well as uses of such methods and products, for example for the treatment of Friedreich ataxia in a subject suffering therefrom. | 2014-10-23 |
20140315783 | PYRIMIDINE DIOL AMIDES AS SODIUM CHANNEL BLOCKERS - The present disclosure provides pyrimidine diol amides of Formula (I), and the pharmaceutically acceptable solvates and prodrugs thereof, wherein A | 2014-10-23 |
20140315784 | Binding Inhibitors of the Beta. Transducin Repeat-Containing Protein - The present invention relates to compounds which bind to Beta Trans-ducin repeat-containing protein (PTrCP), and modulate the activity of 13TrCP. In particular, the invention relates to compounds which demonstrate optimised binding to PTrCP. The invention also relates to pharmaceutical compositions comprising such compounds and the use of such compounds as medicaments, specifically for the treatment of disorders associated with aberrant protein degradation, such as cancer. The preferred binding inhibitors are peptides derived from the motive DSGXXS, e.g. DEGFWE, DDGFWD and Succinyl-EGFWE. | 2014-10-23 |
20140315785 | METHODS RELATED TO THE TREATMENT OF NEURODEGENERATIVE AND INFLAMMATORY CONDITIONS - The invention includes methods of neuroprotection, inducing release of neurotrophic factors, inhibiting the over-activation of innate immune cells, attenuating the toxin-induced death and/or damage of tissues, reducing inflammation, treating an inflammation-related condition, and inhibiting NADPH oxidase, that includes contacting or administering an effective amount of at least one compound of the invention that include: valproic acid, sodium butyrate, and salts thereof; opioid peptides; a peptide comprising the tripeptide GGF; and morphinans, such as naloxone, naltrexone, 3-hydroxy-morphinan and dextromethorphan. | 2014-10-23 |
20140315786 | USE OF INTRACELLULAR ENZYMES FOR THE RELEASE OF COVALENTLY LINKED BIOACTIVES - The present invention relates to targeting an intracellular enzyme for release of covalently linked bioactives which results in a synergistic effect between the bioactives. The present invention relates to the use of bioactives that are directly connected covalently or through a covalent molecular linker which have increased therapeutic activity when released as the free bioactives by intracellular enzymes as compared to when the bioactives are administered individually (i.e. not covalently linked). Further, methods are described of administering to patients in need thereof, bioactives as linked bioactives having increased therapeutic activity. Accordingly, this invention also relates to methods of treating patients for certain diseases. | 2014-10-23 |
20140315787 | Antioxidant, Anti-Inflammatory, Anti-Radiation, Metal Chelating Compounds And Uses Thereof - Potent compounds having combined antioxidant, anti-inflammatory, anti-radiation and metal chelating properties are described. Short peptides having these properties, and methods and uses of such short peptides in clinical and cosmetic applications are described. | 2014-10-23 |
20140315788 | METHODS FOR IMPROVING HEART FUNCTION - The present invention encompasses combination comprising a plurality of amino acids, formulations thereof for use in humans and animals, as well as methods for increasing muscle protein synthesis, muscle strength, and/or muscle function. | 2014-10-23 |
20140315789 | ANTIMICROBIAL PEPTIDES AND USES THEREOF - The present disclosure relates generally to antimicrobial peptides, methods for their use, and methods for preparing devices having surfaces which are modified to incorporate OH said peptides. In some embodiments, the antimicrobial peptides are antimicrobial OH cationic peptides modified to comprise a thiol functional group. | 2014-10-23 |
20140315790 | AMINOTHIAZOLES AND THEIR USES - The present application describes organic compounds that are useful for the treatment, prevention and/or amelioration of diseases. | 2014-10-23 |
20140315791 | METHOD OF MAKING BIOLOGICALLY ACTIVE ALPHA-BETA PEPTIDES - Described is a method of fabricating biologically active, unnatural polypeptides. The method includes the steps of selecting a biologically active polypeptide or biologically active fragment thereof having an amino acid sequence comprising α-amino acid residues, and fabricating a synthetic polypeptide that has an amino acid sequence that corresponds to the sequence of the biologically active polypeptide, but wherein about 14% to about 50% of the α-amino acid residues found in the biologically active polypeptide or fragment of step (a) are replaced with β-amino acid residues, and the α-amino acid residues are distributed in a repeating pattern. | 2014-10-23 |
20140315792 | ANTI-VIRAL COMPOUNDS - Compounds effective in inhibiting replication of Hepatitis C virus (“HCV”) are described. This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection. | 2014-10-23 |
20140315793 | Novel Bacillus Thuringiensis Gene with Lepidopteran Activity - The invention provides nucleic acids, and variants and fragments thereof, obtained from strains of | 2014-10-23 |
20140315794 | ANTIPARISITIC DIHYDROAZOLE COMPOUNDS AND COMPOSITIONS COMPRISING SAME - The present invention relates to novel dihydroazole of formula (I) and salts thereof: | 2014-10-23 |
20140315795 | Compositions and Methods for Selective Delivery of Oligonucleotide Molecules to Cell Types - The invention provides a conjugate comprising (i) a nucleic acid which is complementary to a target nucleic acid sequence and which expression prevents or reduces expression of the target nucleic acid and (ii) a selectivity agent which is capable of binding with high affinity to a receptor which can be internalised by the cell in response to the binding of said selectivity agent. The conjugates of the present invention are useful for the delivery of the nucleic acid to a cell of interest and thus, for the treatment of diseases which require a down-regulation of the protein encoded by the target nucleic acid as well as for the delivery of contrast agents to the cells for diagnostic purposes. | 2014-10-23 |
20140315796 | MODULATORS OF PROTEASE ACTIVATED RECEPTORS - The present invention provides novel compounds of the Formula (I), pharmaceutical compositions comprising such compounds and methods for using such compounds as tools for biological studies or as agents or drugs for therapies such as metabolic syndrome, obesity, type II diabetes, fibrosis and cardiovascular diseases, whether they are used alone or in combination with other treatment modalities. | 2014-10-23 |
20140315797 | Novel N-Terminally Modified Insulin Derivatives - The invention is related to novel N-terminally modified insulin derivatives, pharmaceutical compositions comprising such and methods of making such. | 2014-10-23 |
20140315798 | CHEMICALLY AND THERMODYNAMICALLY STABLE INSULIN ANALOGUES AND IMPROVED METHODS FOR THEIR PRODUCTION - The subject matter of this invention is directed towards chemically and thermodynamically stable single-chain insulin (SCI) analogues that are resistant to deamidation and fibrillation. The invention further discloses improved methods for the recombinant expression, purification and refolding of SCI. | 2014-10-23 |
20140315799 | Compositions and Methods for Regulating Glucose Metabolism - The present disclosure provides compositions for regulating glucose metabolism. The compositions provide for reduced levels of p75 | 2014-10-23 |
20140315800 | Glycosylated Polypeptide and Drug Composition Containing Said Polypeptide - [Problem] To provide a glycosylated polypeptide having affinity to somatostatin receptors and, compared to somatostatins, having improved in-blood stability. [Solution] The glycosylated polypeptide is characterized by at least two amino acids in a somatostatin or an analogue thereof being replaced by glycosylated amino acids. | 2014-10-23 |
20140315801 | METHODS OF TREATMENT OF CELL PROLIFERATIVE AND/OR OPHTHALMIC DISEASES, DISORDERS AND CONDITIONS USING INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY - This invention relates to methods for treating cell proliferative diseases and conditions and ophthalmic diseases, disorders and conditions using compounds that inhibit protein tyrosine kinase activity. In particular the invention relates to the methods of treatment which utilize compounds that inhibit the protein tyrosine kinase activity of growth factor receptors, resulting in the inhibition of receptor signaling, for example, the inhibition of VEGF receptor signaling. | 2014-10-23 |
20140315802 | Derivatisation of Erythropoietin (EPO) - The present invention relates to a compound which is a polysaccharide derivative of EPO, or of an EPO like protein, wherein the polysaccharide is anionic and comprises between 2 and 200 saccharide units. The present invention also relates to pharmaceutical compositions comprising the novel compounds, and methods for making the novel compounds. | 2014-10-23 |
20140315803 | METHODS FOR STIMULATING HAIR GROWTH - A method for promoting hair growth in a human in need of promoting hair growth. The method includes preparing a composition comprising a therapeutically effective amount of at least three of: a Bone Morphogenetic Protein, Transforming Growth Factor Beta, Platelet Derived Growth Factor, Insulin-like Growth Factor, Basic Fibroblastic Growth Factor and Vascular Endothelial Growth Factor; and administering the composition to the human. | 2014-10-23 |
20140315804 | FUSION PROTEINS COMPRISING PDGF AND VEGF BINDING PORTIONS AND METHODS OF USING THEREOF - The present provides fusion proteins comprising PDGF and VEGF binding portions, and recombinant viral particles encoding the fusion proteins. Compositions comprising the fusion proteins and viral particles as well as methods of using the same are also provided. | 2014-10-23 |
20140315805 | LOCALLY RELEASED GROWTH FACTORS TO MEDIATE MOTOR RECOVERY AFTER STROKE - Methods of improving recovery of a mammal after an ischemic event (e.g., stroke) are provided. In various embodiments the methods involve administering a neural growth factor (e.g., BDNF) into the infarct (e.g., stroke) cavity in a biocompatible hydrogel formulation. In certain embodiments the hydrogel comprises a thiolated hyaluronan and a thiolated gelatin with an optional thiolated heparin. | 2014-10-23 |
20140315806 | VETERINARY DECORIN COMPOSITIONS AND USE THEREOF - The present invention relates to veterinary decorin compositions and methods of their production. | 2014-10-23 |
20140315807 | Treatment and Prevention of Bone Loss Using Resolvins - The invention provides new methods for inducing or promoting bone growth and/or for reducing or preventing bone deterioration in a mammal subject. The inventive methods generally comprise administering to the subject an effective amount of a resolving. In particular, the inventive methods may be useful for treating or preventing conditions associated with bone degradation, deterioration or degeneration such as periodontal disease, osteoarthritis, and metastatic bone disease and osteolytic bone disease. Pharmaceutical compositions and kits comprising at least one resolving are also provided that can be used to performed the inventive methods. | 2014-10-23 |
20140315808 | INHIBITION OF THE RENIN-ANGIOTENSIN SYSTEM FOR THE TREATMENT OF RENAL, VASCULAR AND CARTILAGE PATHOLOGY - A method of treating a disease or condition in which up-regulating GAGs is therapeutically beneficial is disclosed. The method comprises locally administering to a subject a therapeutically effective amount of an agent capable of down-regulating activity or expression of a component of the renin-angiotensin system. | 2014-10-23 |
20140315809 | CALCIMIMETICS AND METHODS FOR THEIR USE - Methods for treating subjects suffering from chronic kidney disease-mineral and bone disorder or other disorders resulting in primary or secondary hyperparathyroidism are described. The methods are effective in reducing serum parathyroid hormone (PTH) levels and calcium levels in patients who undergo hemodialysis. The methods described herein are also effective in slowing the progression of kidney disease and preserving kidney function. Compositions used in the described methods are also provided and comprise calcimimetics which function as agonists of the calcium sensing receptor (CaSR). | 2014-10-23 |
20140315810 | AGENT FOR THE TREATMENT OF ALOPECIA - It is an object of the present invention to provide a new agent for the treatment of alopecia, the agent being not only effective and safe for, in particular, alopecia areata, androgenetic alopecia in a male, androgenetic alopecia in a female, female pattern alopecia, postpartum alopecia, seborrheic alopecia, alopecia pityroides, senile alopecia, cancer chemotherapy drug-induced alopecia, and alopecia due to radiation exposure, but also effective for a target having resistance to treatment with minoxidil or finasteride, there being no side effects such as an itching sensation, irritation, or feminization, and no contraindications, the agent suppressing dandruff or having a therapeutic effect for white hair, and the therapeutic effect for alopecia being maintained for a long period even when use of the agent is stopped. | 2014-10-23 |
20140315811 | OPHTHALMIC PREPARATIONS BASED ON PACAP (PITUITARY ADENYLATE CYCLASE ACTIVATING POLYPEPTIDE) WHICH RESTORE THE NORMAL VISUAL FUNCTION IN EARLY GLAUCOMA - The present invention relates to ophthalmic preparations in the form of eyedrops based on PACAP (Pituitary Adenylate Cyclase Activating Polypeptide) which restore the normal visual function in retinal dystrophy/retinopathy and optic neuropathy, with special reference to glaucoma. | 2014-10-23 |
20140315812 | AMORPHOUS EZATIOSTAT ANSOLVATE - Provided herein is an amorphous form of a pharmaceutically acceptable salt of ezatiostat, for example, ezatiostat hydrochloride, compositions, uses and methods of preparation thereof. | 2014-10-23 |
20140315813 | Use of an Active Biological Substance in Abnormal Cellular and Viral Membrane Physiologies - An active biological substance is disclosed for use in abnormal cellular and viral membrane physiologies in human and mammal organisms. The active substance has diagnostic and/or therapeutic properties and contains or consists of at least one component selected from the group of substances including: histones, covalently modified histones, histone-like polypeptides, biologically active histone sequences and histone-like polypeptides as agents for stopping the supply to solid tumours over their blood vessels, for killing cells infected by virus and for killing tumour cells with disturbed lipid asymmetry. | 2014-10-23 |
20140315814 | SYNTHETIC PENTASACCHARIDES HAVING SHORT HALF-LIFE AND HIGH ACTIVITY - The invention concerns a pentasaccharide compound of formula (I) | 2014-10-23 |
20140315815 | USE OF SULFATED GLYCOSAMINOGLYCANS FOR IMPROVING THE BIOAVAILABILITY OF FACTOR VIII - The present invention relates to pharmaceutical preparations comprising one or more Factor VIII and a sulfated glycosaminoglycan for increasing the bioavailability of Factor VIII upon non-intravenous administration. The invention further relates to the combined use of Factor VIII and a sulfated glycosaminoglycan for the treatment and prevention of bleeding disorders, whereby the bioavailability of Factor VIII is increased, and to a method for increasing the bioavailability after non-intravenous administration of Factor VIII by coadminstration of a sulfated glycosaminoglycan. | 2014-10-23 |
20140315816 | ALBUMIN VARIANTS - The invention relates to variants of a parent albumin having altered plasma half-life compared with the parent albumin. The invention also relates to fusion polypeptides and conjugates comprising said variant albumin. | 2014-10-23 |
20140315817 | VARIANT SERUM ALBUMIN WITH IMPROVED HALF-LIFE AND OTHER PROPERTIES - The invention provides methods and materials for making and using variant serum albumin amino acid sequences which exhibit improved properties compared to wild type serum albumin sequences. The invention further provides methods and materials for making and using fusion proteins in which the variant serum albumin amino acid sequences are fused to a therapeutic or diagnostic agent, such as a therapeutic protein, or a functional fragment or variant thereof that maintains activity, and exhibits improved properties. | 2014-10-23 |
20140315818 | METHODS AND PRODUCTS FOR TREATING PREECLAMPSIA AND MODULATING BLOOD PRESSURE - The invention relates to methods for altering biological parameters in a subject, such as reducing blood pressure in a subject, by displacing CLIP, using a CLIP inhibitor. The methods are useful for treating disorders such as preeclampsia and high blood pressure. | 2014-10-23 |
20140315819 | ACTIVE SMALL-MOLECULE DONKEY-HIDE GELATIN MIXTURE AND PREPARATION METHOD AND APPLICATION THEREOF - An active small-molecule donkey-hide gelatin mixture and a preparation method and application thereof. The active small-molecule donkey-hide gelatin mixture is prepared by using the compound protease comprising the proline protease to perform the enzymatic hydrolysis on the donkey-hide gelatin juice to which no auxiliary material is added. For the active small-molecule donkey-hide gelatin mixture, the weight-average molecular weight ranges from 580 Da to 1300 Da, the peptide segments are distributed from 200 Da to 3000 Da, the dissolution rate in cold water is high, and the content of free amino acid is low; the active small-molecule donkey-hide gelatin mixture may be used for manufacturing small-molecule peptide food and health care food of donkey-hide gelatin. | 2014-10-23 |
20140315820 | High-Potency Botulinum Toxin Formulations - The present invention provides improved formulations of botulinum toxin that increase delivery of the botulinum toxin to neural and associated tissues and exhibit a higher specific neurotoxicity and higher potency (in LD | 2014-10-23 |
20140315821 | TREATMENTS INVOLVING ESLICARBAZEPINE ACETATE OR ESLICARBAZEPINE - The invention provides a drug selected from eslicarbazepine acetate and eslicarbazepine, for use in treating or preventing a disorder selected from epilepsy, affective disorders, schizoaffective disorders, bipolar disorders, neuropathic pain and neuropathic pain related disorders, attention disorders, anxiety disorders, sensorimotor disorders, vestibular disorders, and fibromyalgia, in a patient suffering from or susceptible to absence seizures. | 2014-10-23 |
20140315822 | HIGH MAST2-AFFINITY POLYPEPTIDES AND USES THEREOF - The invention relates to polypeptides containing a cytoplasmic domain ending with a MAST-2 binding domain, from 11 to 13 residues, the first two residues of which are S and W, and the last four residues of which are Q, T, R and L, said polypeptides presenting a high affinity for the PDZ domain of the human MAST2 protein. The invention also relates to polynucleotides, vectors, lentiviral particles, cells as well as compositions comprising the same. The invention is also directed to the use of said polypeptides, polynucleotides, vectors, lentiviral particles, cells and compositions in the treatment and/or prevention of a disease, disorder or condition, which alters the Central Nervous System (CNS) and/or the Peripheral Nervous System (PNS). The invention also concerns molecular signatures of cellular genes to determine the neurosurvival and/or neuroprotection activity of a molecule. | 2014-10-23 |
20140315823 | PEPTIDE COMPOUNDS FOR SUPPRESSING INFLAMMATION - Provided herein are peptides that exhibit ApoE biological activity, as well as compositions and pharmaceutical formulations that include the peptides. The peptides, compositions, and methods disclosed herein have broad applications as they can be used to treat a broad spectrum of injury, diseases, disorders, and clinical indications. | 2014-10-23 |
20140315824 | PEPTIDE PREPARATIONS AND PEPTIDES WITH ANTITUMOUR ACTIVITY - The subject of the present invention are peptide preparations obtained via the enzymatic digestion of hair, wool, bristles, animal fur and individual peptides with sequences corresponding to individual components of a peptide preparation with antitumour activity, for use in the treatment of tumours or oncological prophylaxis as basal components or components of compositions of substances for treating tumours or components of substances used in oncological prophylaxis. | 2014-10-23 |
20140315825 | ANTI-CANCER COMPOSITIONS CONTAINING WNT DECOY RECEPTOR - The present invention relates to a composition for preventing or treating cancer comprising Wnt decoy receptor. The composition of the present invention or the expression product thereof inhibits cancer generation, growth, proliferation and metastasis, and induces apoptosis of cancer cells, by binding to Wnt ligand and blocking ligand-receptor interactions, therefore may be effectively used as an anti-cancer agent. | 2014-10-23 |
20140315826 | POLYMERIC CONJUGATES OF C-1 INHIBITORS - Polymer conjugates containing a C1-inhibitor having at least one substantially non-antigenic polymer covalently attached to the C1-inhibitor via glycan group of the C1 inhibitor is provided. In addition, methods of making the conjugates as well as methods of treatment using the conjugate of the present invention are also provided. | 2014-10-23 |
20140315827 | CRYSTALLINE FORM OF CYCLOSPORINE A, METHODS OF PREPARATION, AND METHODS FOR USE THEREOF - The present invention relates generally to crystalline forms of cyclosporine A and particularly to a newly identified form of cyclosporine A. The invention further relates to methods for its preparation and to methods for treating certain ocular disorders. | 2014-10-23 |
20140315828 | CROSS-LINKED SILK-HYALURONIC ACID COMPOSITIONS - Compositions useful as dermal fillers and methods using such compositions to treat various skin and soft tissue conditions. The dermal fillers can comprise silk attached to hyaluronic acid using for example two cross linkers and can be used to treat of facial imperfections, facial defects, facial augmentations, breast imperfections, breast augmentations or breast reconstructions. | 2014-10-23 |
20140315829 | Compositions And Methods For Enhancing Sialic Acid Levels In Tissue - The invention relates to compositions and methods for increasing sialic acid uptake and/or incorporation into tissue following gastrointestinal ingestion of compositions that contain sialic acid. | 2014-10-23 |
20140315830 | RICE-PROTEIN COMPOSITION AND METHOD FOR MANUFACTURING SAME - The objective of the present invention is to provide a high-purity rice-protein composition with improved tongue feel and a melt-in-the-mouth quality, and a method for manufacturing the composition. The rice-protein composition comprises glutelin and prolamine, the protein content with respect to the solid content being at least 90%. Rice protein extracted by an alkaline solution from rice or rice flour is neutralized and coagulated at a temperature no lower than 40 80 DEG C., or is coagulated by adding a divalent metal ion and then neutralized, or glucono-delta-lactone is added and the solution is heated to gel the protein; by therein keeping the pH of the rice-protein composition no lower than 7.0 or no higher than 4.0, a rice-protein composition with extremely good dispersibility and tongue feel can be obtained. Further, by heating to at least 80 DEG C. after adjusting pH, a composition with high water absorbency is achieved. | 2014-10-23 |
20140315831 | Synthesis of Libraries of Peptide Tertiary Amides - The present disclosure is directed to a novel class of peptide-like oligomers called peptide tertiary amides (PTAs) and a combinatorial library of PTAs along with synthetic routes for the preparation of large combinatorial libraries of these compounds. The peptide tertiary amides provide an exceptional source of high affinity and selective protein ligands that are useful as tools for biological research and as drug leads, among others. | 2014-10-23 |
20140315832 | PHARMACEUTICAL COMPOSITION, METHODS FOR TREATING AND USES THEREOF - The present invention relates to certain SGLT-2 inhibitors for treating, preventing, protecting against and/or delaying the progression of chronic kidney disease in patients, for example patients with prediabetes, type 1 or type 2 diabetes mellitus. | 2014-10-23 |
20140315833 | Cocrystalline DHEA Formulations - A cocrystalline DHEA composition with at least one additional coformer is disclosed for therapeutic formulations. The cocrystalline DHEA/coformer formulation including at least one coformer chosen from the group consisting of glutaric acid, maleic acid, tartaric acid, fructose, and wherein the L-isomer of tartaric acid and the D-isomer of fructose are utilized. The cocrystalline DHEA/coformer formulations include certain excipients as a solubilizer or inhibitor. | 2014-10-23 |
20140315834 | COMPOUNDS AND COMPOSITIONS FOR USE IN THE PREVENTION AND TREATMENT OF INFLAMMATION-RELATED DISORDERS, PAIN AND FEVER, SKIN DISORDERS, CANCER AND PRECANCEROUS CONDITIONS THEREOF - The present invention provides novel compounds and pharmaceutical compositions for the prevention and/or treatment of cancer and precancerous conditions thereof, for the treatment of pain and fever, for the treatment of skin disorders, and for treating and/or preventing inflammation-related diseases and/or cardiovascular diseases. The compounds of the invention also have analgesic properties and anti-platelet properties. The compounds of the invention may be provided to animals, including mammals and humans, by administering a suitable pharmaceutical dose in a suitable pharmaceutical dosage form. The compounds of the invention have improved efficacy and safety, including higher potency and/or fewer or less severe side effects, than conventional therapies. The compounds of the invention comprise a biologically active moiety or portion (A) that has, or is modified to have at least one carboxyl group. The moiety A is preferably an aliphatic, aromatic or alkylaryl group, preferably derived from a non-steroidal anti-inflammatory drug or NSAID (A). The moiety A is bound to a linker moiety (B) via the carboxyl of group A and a linking atom that is selected from oxygen, nitrogen, and sulphur, to form a carboxylic ester, and amide, or a thioester, bond (X | 2014-10-23 |
20140315835 | RNAI AGENTS, COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATING TRANSTHYRETIN (TTR) ASSOCIATED DISEASES - The present invention provides RNAi agents, e.g., double stranded RNAi agents, that target the transthyretin (TTR) gene and methods of using such RNAi agents for treating or preventing TTR-associated diseases. | 2014-10-23 |
20140315836 | PROTECTIVE AGENT FOR KERATOCONJUNCTIVA OR SUPPRESSIVE AGENT FOR KERATOCONJUNCTIVAL DISORDER - An object of the present invention is to provide a protective agent for the keratoconjunctiva or a suppressive agent for a keratoconjunctival disorder having an excellent suppressive effect on a keratoconjunctival disorder. The invention relates to a protective agent for the keratoconjunctiva or a suppressive agent for a keratoconjunctival disorder containing glucosylglycerol as an active ingredient, use of glucosylglycerol for the manufacture of a pharmaceutical for protecting a keratoconjunctiva or suppressing a keratoconjunctival disorder and a method of protecting a keratoconjunctiva or suppressing a keratoconjunctival disorder comprising administering glucosylglycerol. | 2014-10-23 |
20140315837 | COMPOSITIONS COMPRISING NORIBOGAINE AND AN EXCIPIENT TO FACILITATE TRANSPORT ACROSS THE BLOOD BRAIN BARRIER - This invention relates generally to compositions comprising noribogaine and an excipient to facilitate transport across the blood brain barrier. | 2014-10-23 |
20140315838 | Methods of Treating Recurring Bacterial Infection - The present invention relates to methods of treating a recurring gastrointestinal (GI) infection of | 2014-10-23 |
20140315839 | PEST CONTROL COMPOSITION INCLUDING NOVEL IMINOPYRIDINE DERIVATIVE - Provided is a pest control composition containing a novel iminopyridine derivative and other pest control agents. | 2014-10-23 |
20140315840 | STABLE INSECTICIDE COMPOSITIONS AND METHODS FOR PRODUCING SAME - Insect controlling compositions including an N-substituted (6-haloalkylpyridin-3-yl)alkyl sulfoximine compound exhibiting increased stability, along with methods for preparing same, are disclosed. | 2014-10-23 |
20140315841 | COMPOSITIONS COMPRISING RIFABUTIN, CLARITHROMYCIN, AND CLOFAZIMINE AND USES THEREOF - Oral administration of a solid dosage form of the present invention comprising an effective amount of rifabutin, an effective amount of clarithromycin, an effective amount of clofazimine, and an effective amount of an absorption enhancer, is used to treat a subject suffering from, or susceptible to, | 2014-10-23 |
20140315842 | Avermectins and Milbemycins as Anti-Mycobacterial Agents - The present invention relates to methods of treating a mycobacterial infection. In particular, this invention relates to methods, uses and compounds for use in treating mycobacterial infections, including | 2014-10-23 |
20140315843 | TOPICAL PHARMACEUTICAL COMPOSITIONS OF THIOCOLCHICOSIDE AND METHYLSULFONYLMETHANE - The present invention relates to a topical pharmaceutical composition of thiocolchicoside and methylsulfonylmethane comprising at least one penetration enhancer and one or more gelling agent. Furthermore, the invention relates to process for preparing the said topical pharmaceutical composition and its use for the treatment of pain and inflammatory symptoms associated with muscle-skeletal system and osteoarthritis. | 2014-10-23 |
20140315844 | MULTI-GENE SIGNATURES FOR PREDICTING RESPONSE TO CHEMOTHERAPY OR RISK OF METASTASIS FOR BREAST CANCER - Exemplary embodiments of the invention provide methods and compositions relating to a multi-gene signature, and subsets thereof, for predicting whether an individual with breast cancer will respond to chemotherapy based on expression of the genes in the multi-gene signature, as well as for prognosing risk of breast cancer metastasis. | 2014-10-23 |
20140315845 | HSP90 INHIBITORS WITH MODIFIED TOXICITY - The invention provides 19-substituted geldanamycin derivatives, and pharmaceutically acceptable salts thereof that are potent Hsp90 binding agents useful for the treatment of, and/or the amelioration of symptoms of, cancer or neurodegenerative disorders. | 2014-10-23 |
20140315846 | ANDROGRAPHIS PANICULATA EXTRACT - An extract of | 2014-10-23 |
20140315847 | DRUG ELUTING GRAFT CONSTRUCTS AND METHODS - The present invention provides, in certain aspects, medical graft products that incorporate multiple drug depots in and/or on the products. One such product is a sheet graft construct, for example for tissue support that includes a sheet graft material with a plurality of drug depots. The drug depots can be hardened deposits formed directly onto the sheet graft material and/or can be capable of eluting a drug for a minimum of 72 hours. | 2014-10-23 |
20140315848 | METHODS FOR TREATING CANCER USING TOR KINASE INHIBITOR COMBINATION THERAPY - Provided herein are methods for treating or preventing a cancer, comprising administering an effective amount of a TOR kinase inhibitor and an effective amount of a cytidine analog to a patient having a cancer. | 2014-10-23 |
20140315849 | THERAPEUTIC AGENT FOR INFLAMMATORY DISEASES, CONTAINING ADENOSINE N1-OXIDE AS AN EFFECTIVE INGREDIENT - The present invention has an object to provide an effective and safe therapeutic agent for inflammatory diseases such as sepsis, hepatitis, and inflammatory bowel disease, and solves the above object by providing a therapeutic agent for inflammatory diseases containing adenosine N1-oxide or a derivative thereof as an effective ingredient. | 2014-10-23 |
20140315850 | 2',3'-Dideoxy-2'-alpha-Fluoro-2'-beta-C-Methylnucleosides and Prodrugs Thereof - The present invention is made to fulfill the foregoing need. Since most of antiHN nucleosides are 2′,3′-dideoxynucleosides that have been proved to be excellent substrates of kinases for the phosphorylations. 2′,3′-Dideoxy-2,-a-fluoro-2′-{3-C-methyl-nucleosides can be considered as one unique class of 2′,3′-dideoxynucleosides to be good substrate of kinases because fluorine mimics hydrogen. It also can be considered as ribo-nucleosides to incorporate into RNA of HCV because 2′-fluorine-a mimics 2′-a-OH group. | 2014-10-23 |
20140315851 | VITAMIN B6 DERIVATIVES OF NUCLEOTIDES, ACYCLONUCLEOTIDES AND ACYCLONUCLEOSIDE PHOSPHONATES - Provided herein are compounds, compositions, and methods of using them to treat infections, neoplastic disease, inflammatory disease, and pain. Such compounds are nucleotides, acyclonucleotides, and ANP phosphonates conjugated with forms and/or moieties of Vitamin B6 for delivery past the cell membrane and into the cell. | 2014-10-23 |
20140315852 | NUCLEOSIDE PHOSPHORAMIDATE PRODRUGS - Disclosed herein are phosphoramidate prodrugs of nucleoside derivatives for the treatment of viral infections in mammals, which is a compound, its stereoisomer, salt (acid or basic addition salt), hydrate, solvate, or crystalline form thereof, represented by the following structure: | 2014-10-23 |
20140315853 | METHODS, FORMULATIONS, AND KITS FOR RAPIDLY REPLETING FOLATE LEVELS IN WOMEN - Disclosed are methods for rapidly repleting folate levels of a woman for whom there is reason to believe that she may be pregnant or of a woman who believes that she may soon become pregnant. One of the methods includes administering to the woman two or more repletion doses of folate, wherein each of the repletion doses comprises no less than about 2.5 micromole of folate, wherein the repletion doses are administered no more than about one day apart, and wherein the total number of repletion doses administered to the woman is 72 or fewer. | 2014-10-23 |
20140315854 | BIOTECHNOLOGICAL SULPHATED CHONDROITIN SULPHATE AT POSITION 4 OR 6 ON THE SAME POLYSACCHARIDE CHAIN, AND PROCESS FOR THE PREPARATION THEREOF - The present invention discloses a process for the production of chondroitin sulphate with an average molecular weight (Mw) of 10-30 kDa by chemical sulphation starting from an unsulphated chondroitin backbone, obtained in turn by acid hydrolysis of capsular polysaccharide K4 made directly from | 2014-10-23 |
20140315855 | Antidandruff Agent Sulfated Polysaccharides - The invention relates to the cosmetic use of a sulfated polysaccharide chosen from: dextran sulfate and sulfated polysaccharides derived from the red alga | 2014-10-23 |
20140315856 | AMINOPYRAZOLE DERIVATIVE - A method for treating cancer that includes administering a pharmaceutically effective amount of a composition containing a compound represented by formula (I) or a pharmacologically acceptable salt thereof. In the formula, A represents a 5- to 10-membered heteroaryl group, or a C | 2014-10-23 |